Concepedia

Rodolfo F. Perini

RF

Statistics

Publications

90

Citations

15.3K

H-Index

36

Active since

1995

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Fox Chase Cancer Center

Université Laval

Rodolfo F. Perini is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and pembrolizumab therapy.

ORCID

Publications per year

1995–2025

90

Publications

90

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

, , +9

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

, , +17

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

, , +12

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

, , +12

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

, , +13

1–5 of 90